ERAS — Erasca, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1761918 ·
Last close
$13.89
Market Cap
$4.87B
52W High
$24.28
52W Low
$2.71
ADV30
5,532,589
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -59,521,000 | -51,331,000 | 998,936,000 | 118,959,000 | 82,198,000 |
| Jun 2026 | 0 | — | -47,619,000 | -44,079,000 | 435,054,000 | 42,542,000 | 73,185,000 |
| Mar 2026 | 0 | — | -37,911,000 | -183,440,000 | 461,234,000 | 47,256,000 | 67,706,000 |
| Dec 2025 | 0 | — | -32,604,000 | -29,092,000 | 396,154,000 | 73,805,000 | 70,983,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-98,022,000
Investing CF
$-173,923,000
Financing CF
$248,344,000
CapEx
$-154,059,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.95
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,119,728,000
Inventory
—
Receivables
—
ST Investments
$226,196,000
EBIT TTM
$-150,680,000
Pretax Income TTM
$-287,223,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -131,405,000 | -124,546,000 | 396,154,000 | 70,983,000 | 325,171,000 | -95,455,000 |
| Dec 2024 | 0 | -157,087,000 | -161,650,000 | 502,526,000 | 79,027,000 | 423,499,000 | -109,417,000 |
| Dec 2023 | 0 | -141,525,000 | -125,042,000 | 395,297,000 | 78,611,000 | 316,686,000 | -101,217,000 |
| Dec 2022 | 0 | -145,450,000 | -242,805,000 | 514,909,000 | 103,056,000 | 411,853,000 | -103,264,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-287,223,000
OpCashFlow TTM
—
Assets (Latest)
$435,054,000
Forward EPS
$-0.75
Max Pain — expiry 2026-12-18
max pain strike: $12.50 · spot: $13.76 · call oi: 11,669 · put oi: 3,892
Expected Move to 2026-12-18:
±$5.00
(36.34%) —
implied range
$8.76 –
$18.76
· ATM straddle on $14.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $4.90B | $86.98 | — |
| COGT | Cogent Biosciences, Inc. | $4.85B | $27.85 | — |
| TVTX | Travere Therapeutics, Inc. | $4.91B | $51.10 | — |
| PTCT | PTC THERAPEUTICS, INC. | $5.04B | $60.36 | — |
| GIKLY | Grifols SA | $4.69B | $5.55 | — |
News headlines (Yahoo Finance, 1h cache)
Erasca Partners With Bristol Myers Squibb to Evaluate ERAS-0015 Combination Treatment for Pancreatic Cancer
2026-11-18 11:43 · Yahoo
Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
2026-11-17 23:40 · Yahoo
Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
2026-11-16 13:01 · Yahoo
Erasca Reports Third Quarter 2026 Business Updates and Financial Results
2026-11-12 21:01 · Yahoo
Erasca Stock In Focus As Combination Trial Begins
2026-11-12 03:13 · Yahoo
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
2026-11-04 13:30 · Yahoo
Erasca to Present at Upcoming Conferences in November
2026-11-03 13:00 · Yahoo
Erasca (ERAS), What Is Driving Attention Around The Stock Today?
2026-10-27 18:15 · Yahoo
Erasca (ERAS) Stock Looks Above Fair Value After Its 5x Run
2026-10-19 06:08 · Yahoo
Sector Update: Healthcare Stocks Mixed Friday Afternoon
2026-10-16 17:44 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.